3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 3
1
Phase 2
1
Status
Recruiting
4
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
4
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
4
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
entrectinib
×
Clear all
NCT05862285
2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3
Recruiting
100 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled